viTToria biotherapeutics
Jay Mohr is an experienced executive in the biotechnology and healthcare sectors, currently serving as the EVP and Chief Business Officer at New York Blood Center since August 2020, where responsibilities include overseeing blood products and advancing research in therapeutics. Mohr holds positions as a General Partner at NYBC Ventures, aiming to foster innovation in blood-related fields, and as a Board Observer for companies such as Immusoft and Vittoria Biotherapeutics, Inc. Previously, Mohr held leadership roles at AZTherapies, Inc., Dirigo Therapeutics, LLC, and Locust Walk, contributing significantly to the development and commercialization of biopharmaceuticals. Mohr's academic credentials include an MBA from The Wharton School and a BA from Vanderbilt University.
This person is not in any teams
This person is not in any offices
viTToria biotherapeutics
Vittoria Biotherapeutics develops gene-edited cell therapies. they provide next-generation, paradigm-shifting T-cell therapeutics that address unmet medical needs. Senza5 Technology from viTToria improves the efficacy, safety, and utility of cell-based treatments in preclinical settings.